BIOFORCE                  1415 Golden Aspen Drive            PHN 1-515.233.8333
NANOSCIENCES              Suite 101                          FAX 1-515.233.8337
                          Ames, IA  50010-8090 USA


FOR RELEASE: January 15, 2007, 9:30 a.m. EDT

Contact: Deb Happe, Director of Communications
                  515-233-8333, Ext. 123
                  dhappe@bioforcenano.com


               BIOFORCE NANOSCIENCES HIRES CHIEF FINANCIAL OFFICER

AMES, IA--BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH.OB) announced today
the  appointment of Gregory D. Brown as the company's  chief  financial  officer
(CFO).

As CFO, Brown is responsible for all company accounting practices, including its
financial strategy,  as well as public company compliance  requirements and fund
raising.

"I am very pleased to have Greg join our executive  team," says Eric  Henderson,
BioForce  Nanosciences'  chief  executive  officer and founder.  "His  extensive
experience  in  financial  and  operational  management  roles  with  technology
companies,   including   attracting  and  structuring   equity  investments  and
developing cost containment strategies,  will make him a valuable contributor as
we continue to execute on our growth strategy."

Brown joins  BioForce  Nanosciences  from his CFO  position  with the  Wisconsin
company,   BidRx,  an  Internet-based   marketplace  for  consumer  purchase  of
prescription  pharmaceuticals.  Prior to working at BidRx,  Brown  worked as the
co-chief  operating officer and partner at Residex Ventures.  At Residex,  Brown
was responsible  for the management of seven portfolio  companies and optimizing
their operational results and strategic direction.



About BioForce Nanosciences, Inc.
- ---------------------------------
BioForce   Nanosciences,   Inc.  is  a  wholly  owned   subsidiary  of  BioForce
Nanosciences Holdings, Inc. (OTC BB: BFNH.OB). BioForce Nanosciences is a unique
development stage company entering into  commercialization with over a decade of
research and accomplishment in the field of  bionanotechnology.  The Company has
demonstrated  the ability to take a product from concept to commercial sale. The
innovative Nano eNabler(TM)  molecular printer provides a platform for practical
technology components for the life science  professional.  For more information,
visit www.bioforcenano.com.

This news release contains  forward-looking  information that may be affected by
certain  risks  and  uncertainties,  including  those  risks  and  uncertainties
described in the Company's  most recent filings with the Securities and Exchange
Commission.  The  Company's  actual  results could differ  materially  from such
forward-looking  statements. We assume no duty to update these statements at any
future date.